Soleus Capital is a healthcare investment firm focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics. Founded in 2018 and based in Greenwich, CT, the firm manages hedge, private equity, and credit funds primarily focused on healthcare-related companies across the United States.
51% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $124.6M (across 42 rounds with reported amounts).
Portfolio
41
Fund Size
—
Top Stage
Series B
Last 12 Mo
3
Team
SM
Steve Musumeci
Founding Partner
BL
Benjamin Lund
Partner
DC
David Canner
Partner
BW
Ben Wessner
Principal
CM
Connor McDermott
Analyst
RB
Ryan Berry
Biotech Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
45 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| BBridge To Life | Bridge | — | Aug 2026 |
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
| CCrystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
 Pillar Biosciences | Series B | $34.5M | May 2025 |
 Neurona Therapeutics | Unknown | $102M | Apr 2025 |
| AAbcuro, Inc. | Series C | $200M | Feb 2025 |
 Star Therapeutics | Series D | $125M | Jan 2025 |
 OrganOx | Unknown | $142M | Jan 2025 |
| BBlue Earth Therapeutics Ltd | Series A | $76.5M | Oct 2024 |
 Compass Pathways | Unknown | $285M | Aug 2023 |
 Parse Biosciences | Unknown | $50M | Jan 2023 |
 Beta Bionics | Series C | $57M | Feb 2022 |
| BBeta Bionics, Inc. | Series C | $57M | Feb 2022 |
 RayzeBio | Series D | $160M | Jan 2022 |
 Freenome Inc | Series D | $300M | Dec 2021 |
 Antios Therapeutics | Series B | $75M | Nov 2021 |
| AAntios Therapeutics, Inc. | Series A | $75M | Nov 2021 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Artios Pharma | Series C | $153M | Jul 2021 |
 Artios Pharma | Series C | $153M | Jul 2021 |
 GenapSys | Series D | $70M | May 2021 |
| AAntios Therapeutics, Inc. | Series B | $96M | Apr 2021 |
 IO Biotech | Series B | — | Jan 2021 |
| AArcellx, Inc. | Series C | $115M | Jan 2021 |
Page 1 of 2
Top Co-Investors
RA Capital Management20 shared
Cormorant Asset Management12 shared
Perceptive Advisors10 shared
Pontifax8 shared
Farallon Capital Management7 shared
HBM Healthcare Investments7 shared
Samsara BioCapital7 shared
Foresite Capital7 shared
RTW Investments, LP6 shared
LifeSci Venture Partners6 shared
Logos Capital6 shared
OrbiMed6 shared
ArrowMark Partners5 shared
Sixty Degree Capital5 shared
Deep Track Capital5 shared
Avidity Partners5 shared
Frazier Life Sciences5 shared
Redmile Group5 shared
Eventide Asset Management4 shared
Adage Capital Management4 shared
Last updated: 8 September 2026